WARREN, NJ, Nov. 28, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. (NYSE American:...
WARREN, NJ, Sept. 18, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or...
Transaction Provides Timber Stockholders with Upfront Cash Consideration and Downstream Value through...
WARREN, NJ, July 03, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – Timber Pharmaceuticals, Inc. ("Timber" or...
- First Presentation of Data From Phase 3 ASCEND Study Will Feature Pharmacokinetic Results That Indicate...
- Phase 3 ASCEND study of TMB-001 (topical isotretinoin) for the treatment of congenital ichthyosis is 70...
- Timber has now Enrolled Over 60% of Patients for Pivotal TMB-001 Phase 3 ASCEND Clinical Trial - WARREN, NJ...
- Lead asset TMB-001 is only compound to receive official orphan drug designation from European Commission for...
- Treatment with TMB-001 demonstrated greater proportions of participants achieving primary and key secondary...
Company Progressing With Pivotal Phase 3 ASCEND Clinical Trial in the U.S., Canada, Italy, France, and Germany...
Virtual Business Briefing With Q&A to be Webcast on December 20, 2022 at 10:30 am ET BASKING RIDGE, NJ...
BASKING RIDGE, NJ, Dec. 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc...
-Timber Received Orphan Designation from European Commission for Lead Asset TMB-001- -Recruitment for the...
0001504167false--12-3100015041672022-11-072022-11-07UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM...
0001504167false00015041672022-11-072022-11-07UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.